Cardio Diagnostics Holdings (CDIO) Stock Analysis & AI Equity Report
Cardio Diagnostics Holdings (CDIO) overview
Cardio Diagnostics Holdings (CDIO) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -6.5m; the year-end share price was 2.71 USD and market capitalisation was USD 4.9m. Cardio Diagnostics Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Cardio Diagnostics Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Cardio Diagnostics Holdings
Cardio Diagnostics develops clinical blood tests and related tools for cardiovascular disease risk assessment and detection using an AI-driven platform combining genetic and epigenetic information. Its products include tests focused on coronary heart disease and a platform that provides clinicians with genetic and epigenetic insights for patient management. The company also offers a research-use solution supporting cardiovascular biopharmaceutical discovery and development.
Generate the Cardio Diagnostics Holdings report
Cardio Diagnostics Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Cardio Diagnostics Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Cardio Diagnostics Holdings
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.